Home
    Disclaimer
    MGM-15 molecular structure

    MGM-15 Stats & Data

    M-p Pseudo Mitragynine pseudoindoxyl
    NPS DataHub
    MW414.5
    FormulaC23H30N2O5
    IUPACmethyl (E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3-oxospiro[1H-indole-2,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate
    SMILESCOC=C(C(=O)OC)C1CC2N(CCC23Nc2cccc(OC)c2C3=O)CC1CC
    InChIKeyBAEJBRCYKACTAA-WGUOAFTMSA-N
    Chemical Class Opioid
    Psychoactive Class Depressant / Psychedelic
    Half-Life Unknown in humans (anecdotal duration suggests multi-hour activity)

    Effect Profile

    Curated
    Psychedelic 4.1

    Strong auditory effects with mild visuals, low body load and headspace

    Visual Intensity×3
    4
    Headspace Depth×3
    1
    Auditory Effects×1
    10
    Body Load / Somatic Effects×1
    2
    Opioid 6.6

    Strong euphoria with moderate sedation and itching/nausea, mild pain relief

    Euphoria / Warmth×3
    9
    Analgesia×2
    4
    Sedation / Relaxation×1
    7
    Itching / Nausea×1
    6

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans (anecdotal duration suggests multi-hour activity)
    Addiction Potential
    High (opioid-class). Rapid tolerance and dependence are possible with daily use; some users report multiple daily dosing or substitution for other opioids/7-OH.

    Tolerance Decay

    Full tolerance 3d Half tolerance 5d Baseline ~21d

    Opioid-class tolerance can develop quickly with daily use; users report ‘losing effect’ within days. Cross-tolerance with other opioids is expected but extent is uncertain. Very limited empirical data exist for MGM-15; estimates are extrapolated from opioid pharmacology and user reports. Data quality: anecdotal.

    Cross-Tolerances

    7-hydroxymitragynine
    80% ●○○
    mitragynine/kratom
    50% ●○○
    classical opioids (morphine, oxycodone, fentanyl)
    70% ●○○

    Harm Reduction

    drugs.wiki

    MGM-15 is a semi-synthetic analogue of the kratom alkaloid 7-hydroxymitragynine (7-OH) developed alongside MGM-16 as mu/delta-opioid dual agonists; animal and in vitro work consistently finds MGM-16 more potent than MGM-15. Human pharmacokinetics for MGM-15 are unknown; harm-reduction dosing must rely on cautious titration and user reports. Duration reported online is often longer than 7-OH (many reporting 6–12 h), which increases overdose risk if redosing too early; establish a hard session limit and wait at least several hours before considering any redose. Do not combine with other depressants; animal data show 7-OH causes naloxone-reversible respiratory depression, so kratom-derived opioids should be assumed capable of dangerous respiratory effects, especially in combinations. Carry naloxone if using opioids; instruct bystanders on overdose response. Product variability is extreme: vendors may sell different salts/purities and the label “MGM-15” can refer to nonidentical products; start low, weigh doses precisely (0.001 g scale) or use volumetric dosing, and avoid eyeballing. Because identity is often uncertain, lab drug checking (e.g., LC–MS/GC–MS) is preferred; reagent kits are presumptive at best and cannot quantify potency. Many report that MGM-15 ‘lasts longer but is less euphoric’ than 7-OH; others report needing much higher doses—likely reflecting tolerance, salt form, and adulteration. Expect opioid-class effects/adverse effects: miosis, pruritus, constipation, nausea, sedation, and potential respiratory depression. If aiming to stop use or transition to buprenorphine, wait for clear opioid withdrawal before induction to avoid precipitated withdrawal; seek medical support. Avoid nasal use; at least one community report describes concerning neurological symptoms after several days of intranasal dosing. For rectal administration, dilute, lubricate, use clean equipment, and avoid frequent redosing to reduce local irritation. Driving or operating machinery while sedated is unsafe; impairment can persist into the next day.

    ← Back to MGM-15